Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15093530 | 0.85 | — | — | |
| SCHEMBL245962 | 0.81 | NT5E (0.35) | — | |
| SCHEMBL11985971 | 0.78 | POLB (0.42) | POLBCYP1A2ALDH1A1NR4A2KDM4E | |
| SCHEMBL242075 | 0.76 | BRD4 (0.40) | CYP1A2ALDH1A1NR4A2KDM4ELMNA | |
| SCHEMBL244694 | 0.75 | MAPT (0.41) | POLBCYP1A2ALDH1A1NR4A2KDM4E | |
| SCHEMBL245884 | 0.74 | POLB (0.44) | POLBCYP1A2ALDH1A1NR4A2KDM4E | |
| Bromide SCHEMBL15093306 | 0.73 | MAPT (0.40) | POLBCYP1A2ALDH1A1NR4A2KDM4E | |
| SCHEMBL15182719 | 0.72 | POLB (0.38) | POLBCYP1A2ALDH1A1KMT2A | |
| SCHEMBL250684 | 0.70 | MAPT (0.35) | POLBCYP1A2ALDH1A1OPRK1KMT2A | |
| SCHEMBL14573267 | 0.70 | ALDH1A1 (0.51) | POLBCYP1A2ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588455-B1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-2588455-B1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9376392-B2 | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376392-B2 | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376392-B2 | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9296758-B2 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296758-B2 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296758-B2 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150045374-A1 | 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150045374-A1 | 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150045374-A1 | 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2013103724-A1 | 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| WO-2013103724-A1 | 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| EP-2588455-A1 | 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003498-A1 | 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003498-A1 | 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045374-A1 | 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS | NFATC1, ACIN1, TERT | POLB 1719/4885CYP1A2 2030/4885ALDH1A1 350/4885 |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | NFATC1, ACIN1, ARF1 | POLB 1638/4885CYP1A2 1018/4885ALDH1A1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.